Biopharma companies would get a three-year grace period before new US pediatric cancer study requirements kick in under FDA user fee legislation expected to come up for a House vote this week.
The latest version of the FDA Reauthorization Act (FDARA) (H.R.2430) released July 10 would require pediatric studies for certain molecularly...